GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
Open Access
- 20 March 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (6) , 1001-1010
Abstract
There is a need for biomarkers to predict and measure the severity of immune effector cell–associated neurotoxicity syndrome (ICANS). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are well-validated biomarkers of astroglial and neuronal injury, respectively. We hypothesized that pretreatment GFAP and NfL levels can predict the risk of subsequent ICANS and that increases in GFAP and NfL levels during treatment reflect ICANS severity. We measured cerebrospinal fluid GFAP (cGFAP) and NfL (cNfL) along with serum NfL (sNfL) levels at pretreatment and day 7 to 10 after chimeric antigen receptor (CAR) T-cell infusion in 3 pediatric cohorts treated with CD19- or CD19/CD22-directed CAR T cells. cGFAP and cNfL levels increased during grade ≥1 ICANS in patients treated with CD19-directed CAR T cells but not in those who received CD19/CD22-directed CAR T cells. The sNfL levels did not increase during ICANS. Prelymphodepletion cGFAP, cNfL, and sNfL levels were not predictive of subsequent ICANS. Elevated baseline cGFAP levels were associated with a history of transplantation. Patients with prior central nervous system (CNS) radiation had higher cNfL levels, and elevated baseline sNfL levels were associated with a history of peripheral neuropathy. Thus, cGFAP and cNfL may be useful biomarkers for measuring the severity of CNS injury during ICANS in children. Elevated baseline levels of cGFAP, cNfL, and sNfL likely reflect the cumulative injury to the central and peripheral nervous systems from prior treatment. However, levels of any of the 3 biomarkers before CAR T-cell infusion did not predict the risk of ICANS.Keywords
This publication has 42 references indexed in Scilit:
- Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaCancer Discovery, 2018
- Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood CancerJournal of Clinical Oncology, 2018
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman PrimatesCancer Discovery, 2018
- Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaJAMA Oncology, 2018
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood, 2017
- Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and SimoaClinical Chemistry and Laboratory Medicine (CCLM), 2016
- CSF and Blood Levels of GFAP in Alexander Diseaseeneuro, 2015
- Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 PatientsPLOS ONE, 2014
- Astrocyte–endothelial interactions at the blood–brain barrierNature Reviews Neuroscience, 2006